|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00331175 |
|
Date of registration:
|
26/05/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
|
|
Scientific title:
|
A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects |
|
Date of first enrolment:
|
July 2006 |
|
Target sample size:
|
31 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00331175 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Pfizer CT.gov Call Center |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Pfizer |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- BMI 27-35 kg/m2
Exclusion Criteria:
- Women of childbearing potential
Age minimum:
18 Years
Age maximum:
55 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Obesity
|
|
Intervention(s)
|
|
Drug: Peptide YY3-36
|
|
Primary Outcome(s)
|
|
Food intake
|
|
Secondary Outcome(s)
|
|
Plasma biomarkers, safety, toleration
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|